Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

60.92EUR
21 Jul 2017
Change (% chg)

€0.39 (+0.64%)
Prev Close
€60.53
Open
€60.68
Day's High
€61.35
Day's Low
€60.65
Volume
258,478
Avg. Vol
410,737
52-wk High
€79.05
52-wk Low
€54.84

Latest Key Developments (Source: Significant Developments)

UCB Q1 Cimzia sales up at 317 million euros
Monday, 24 Apr 2017 01:41am EDT 

April 24 (Reuters) - UCB SA ::Q1 immunology/Cimzia sales 317 million euros ($344 million) versus 281 million euros year ago.Q1 Vimpat sales 239 million euros versus 188 million euros year ago.Q1 Neupro sales 73 million euros versus 71 million euros year ago.Q1 Keppra sales 210 million euros versus 168 million euros year ago.Q1 revenue 1.124 million euros versus 974 million euros year ago.Expects 2017 revenue to reach 4.25 - 4.35 billion euros .Expects 2017 recurring EBITDA increase to 1.15 - 1.20 billion euros .Core earnings per share are expected in the range of 3.70 – 4.00 euros based on an expected average of 188 million shares outstanding.  Full Article

UCB and Q-State enter into multi-yr therapeutics discovery collaboration
Tuesday, 4 Apr 2017 01:09am EDT 

UCB SA : And Q-state biosciences form research collaboration to develop novel therapeutics for genetic subtypes of epilepsy . Financial terms are not being disclosed, nor are the genetic targets that are the subject of the research .Program includes research support, as well as prospective preclinical and clinical milestones and royalties.  Full Article

UCB FY revenue, operating profit ahead of Reuters poll
Thursday, 23 Feb 2017 01:12am EST 

UCB SA : Reports FY revenue of 4.18 billion euros ($4.42 billion) versus 4.12 billion euros in Reuters poll . FY Cimzia sales 1.31 billion euros versus 1.28 billion euros in Reuters poll . FY Vimpat sales 814 million euros versus 798 million euros in reuters poll . Fy Keppra sales 724 million euros versus 696 million euros in Reuters poll . Fy Neupro sales 302 million euros versus 296 million euros in Reuters poll . FY REBIT 796 million euros versus 748 million euros in Reuters poll . FY net profit group share 520 million euros versus 623 million euros a year ago . Board of directors of ucb proposes a dividend of 1.15 euros per share (gross), an increase by five eurocents or by 4.5 pct . UCB expects 2017 revenue to reach 4.25-4.35 billion euros; recurring Ebitda should increase to 1.15–1.20 billion euros .2017 core earnings per share are expected in the range of 3.70–4.00 euros based on an expected average of 188 million shares outstanding.  Full Article

UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures
Thursday, 19 Jan 2017 12:00pm EST 

UCB SA :UCB files Briviact (brivaracetam) CV in the US as monotherapy treatment for adult epilepsy patients with partial-onset seizures.  Full Article

Final CIMZIA Phase 3 trial meets primary efficacy endpoint
Thursday, 19 Jan 2017 02:12am EST 

Dermira Inc : Final CIMZIA® (Certolizumab Pegol) phase 3 trial meets primary efficacy endpoint in patients with moderate-to-severe chronic Plaque Psoriasis . Says UCB intends to submit marketing applications to regulatory authorities in Q3 of 2017 .Dermira Inc - CIMZIA demonstrated statistically significant improvements for all primary or co-primary endpoints compared to placebo.  Full Article

UCB announces EU approval for Vimpat as monotherapy
Tuesday, 20 Dec 2016 01:06am EST 

UCB SA : Vimpat EU monotherapy approval . European commission approved license extension for Vimpat (lacosamide) for use as monotherapy in treatment of partial-onset seizures in adult and adolescent patients with epilepsy .Approval comes into immediate effect.  Full Article

UCB and Amgen seek marketing approval of romosozumab in Japan
Monday, 19 Dec 2016 07:00pm EST 

UCB SA :Says Amgen and UCB announce submission of application for investigational osteoporosis medication romosozumab in Japan.  Full Article

Evogen and UCB announce collaboration for EvoScore Start
Monday, 5 Dec 2016 07:00am EST 

UCB SA :Evogen and UCB announce collaboration for further development of EvoScore START for improved diagnosis of epilepsy.  Full Article

Amgen and UCB say FDA accepts biologics license application for romosozumab
Monday, 26 Sep 2016 04:00pm EDT 

Amgen Inc : Amgen and UCB announce FDA acceptance of biologics license application for romosozumab .Amgen says FDA has set a prescription drug user fee act (pdufa) target action date of July 19, 2017, for romosozumab.  Full Article

UCB says Delaware court confirms validity Vimpat patent
Monday, 15 Aug 2016 02:49am EDT 

UCB SA : Announced on Sunday that the Delaware District Court confirmed the validity of U.S. patent RE38,551 related to Vimpat .Decision is currently under seal and will be released following an order from the court.  Full Article

BRIEF-UCB's Bimekizumab demonstrates skin clearance in psoriasis study

* READY TO ADVANCE PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR BIMEKIZUMAB IN PSORIASIS